MGCD-265,
875337-44-3,
MGCD265,
MGCD-265 analog,
MGCD 265,
N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide,
UNII-93M6577H9D,
CHEMBL254760,
93M6577H9D,
n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide,
N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide,
N-((3-Fluoro-4-((2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-phenylacetamide,
N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide,
mgcd-265-analog,
compound 10a [PMID: 18434145],
cc-38,
MLS006010962,
GTPL9133,
SCHEMBL3576588,
C26H20FN5O2S2,
MGCD-265/MGCD265,
BDBM24498,
CHEBI:91393,
DTXSID60647874,
EX-A051,
MGCD265, MGCD-265,
BCPP000164,
HMS3654P17,
ABP000138,
MFCD17779287,
MGCD 265 analog;MGCD265 analog,
s1361,
ZINC29043709,
AKOS015904513,
BCP9000924,
CS-0188,
RL05449,
NCGC00346510-01,
NCGC00346510-04,
4CA-0817,
AJ-83614,
AK102632,
BC659945,
Benzeneacetamide, N-(((3-fluoro-4-((2-(1-methyl-1H-imidazol-4-yl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)amino)thioxomethyl)-,
HY-10991,
SC-85840,
SMR004702766,
FT-0746707,
SW219463-1,
thieno[3,2-b]pyridine-based inhibitor, 10a,
X7487,
W-5695,
J-523005,
BRD-K56277358-001-01-8,
I14-17030,
N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno,
1-(3-fluoro-4-{[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-3-(2-phenylacetyl)thiourea,
3-(3-fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-1-(2-phenylacetyl)thiourea,
N-(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-N'-(phenylacetyl)thiourea,
N-[[[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-benzeneacetamide,
N-[[[3-Fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]benzeneacetamide,
glesatinib,
D08FDX,
CB11946,
A5057,
A10587,